Akari Therapeutics Announces Corporate Update with New Positive Clinical Data and a New Pipeline of Tick Derived and Engineered Proteins

NEW YORK and LONDON, December 5th, 2016 – Phase Ib cohorts demonstrate dose effect and additional support for once daily dosing- -PAS-Coversin pre-clinical data supports once weekly dosing- -Phase II PNH patients identified with data expected 1Q17- -Eculizumab resistant PNH patient treated for over 9 months with Coversin- -New pipeline of tick derived and engineered proteins- -Coversin engineered protein targeting neuromuscular junction for myasthenia gravis- -Proteins targeting two additional pathways as well as second complement inhibitor- NEW YORK and LONDON, December 5th, 2016 (GLOBE NEWSWIRE) — Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced several corporate updates that were discussed during an Analyst & Investor Symposium held during the 58th American Society of Hematology meeting. The corporate presentation is available at https://akaritx.com/event/ash-analyst-investor-symposium/. Click here to see full release

The release as fetched from its publisher. akaritx.com ↗